约翰逊和约翰逊获得FDA批准,用于治疗中度至重症牛皮的新口服药物icotyde在试验中显示出强大的疗效和安全性. Johnson & Johnson gained FDA approval for icotyde, a new oral drug for moderate-to-severe psoriasis, showing strong efficacy and safety in trials.

约翰逊和约翰逊已获得FDA批准,用于治疗中度至重症斑块性牛皮的第一类口服IL-23受体. Johnson & Johnson has received FDA approval for icotyde, a first-in-class oral IL-23 receptor peptide, for moderate-to-severe plaque psoriasis. 根据参与2500名患者的第三期试验,该药物在16周时70%达到近乎清洁的皮肤,55%达到了90%的牛皮严重程度改善,安全性概况与安慰剂相比52周后. Based on Phase 3 trials involving 2,500 patients, the drug showed 70% achieved near-clear skin and 55% reached 90% improvement in psoriasis severity by Week 16, with safety profiles comparable to placebo through 52 weeks. 批准于2026年3月18日宣布,提供一种新的口腔治疗方案,尽管价格和可用性细节仍未公布. The approval, announced March 18, 2026, offers a new oral treatment option, though pricing and availability details remain undisclosed. 尽管取得了这一里程碑,但约翰逊和约翰逊的股票下跌,反映出该行业更广泛的衰退以及最近FDA批准后市场情绪谨慎. Despite the milestone, Johnson & Johnson’s stock declined, reflecting broader sector downturns and cautious market sentiment following recent FDA approvals.